Discover 213 paid clinical trials in Knoxville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 213
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
for
Advanced Melanoma
Location: Knoxville TN, Atlanta GA, Louisville KY, Chapel Hill NC,
Sponsor: Replimune, Inc.
Sex: All
Age: 12+
Code: NCT06264180
Phase 3, Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
for
Carcinoma, Non-Small-Cell Lung
Location: Knoxville TN, Chattanooga TN, Atlanta GA, Nashville TN,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06667076
Phase 2, Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
for
Extrapulmonary Neuroendocrine Cancer (epNEC)
Location: Knoxville TN, Atlanta GA, Nashville TN, St Louis MO,
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT07544654
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
for
Pancreatic Neoplasm
Location: Knoxville TN, Greenville SC, Atlanta GA, Nashville TN,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 50 - 70+
Code: NCT04239573
Recruiting
E-Mindfulness Approaches for Living After Breast Cancer
Location: Knoxville TN, Atlanta GA, Nashville TN, Charlotte NC,
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Sex: All
Age: 18+
Code: NCT04031677
Phase 3, Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)